CHF8.82
3.89% day before yesterday
SIX Swiss Exchange, Dec 27, 05:30 pm CET
ISIN
IT0004147952
Symbol
NWRN
Sector
Industry

Newron Pharmaceutical Stock price

CHF8.82
+1.32 17.60% 1M
+0.57 6.91% 6M
+3.87 78.18% YTD
+3.82 76.40% 1Y
+7.22 451.94% 3Y
+2.33 35.90% 5Y
-17.53 66.53% 10Y
SIX Swiss Exchange, Closing price Fri, Dec 27 2024
+0.33 3.89%
ISIN
IT0004147952
Symbol
NWRN
Sector
Industry

Key metrics

Market capitalization CHF171.63m
Enterprise Value CHF206.94m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 30.93
P/S ratio (TTM) P/S ratio 25.65
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -22.30%
Revenue (TTM) Revenue CHF6.69m
EBIT (operating result TTM) EBIT CHF-14.40m
Free Cash Flow (TTM) Free Cash Flow CHF-12.69m
EPS (TTM) EPS CHF-0.99
P/E forward 7.79
P/S forward 6.10
EV/Sales forward 7.35
Show more

Is Newron Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Newron Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Newron Pharmaceutical:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Newron Pharmaceutical:

Buy
100%

Financial data from Newron Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
6.69 6.69
22% 22%
100%
- Direct Costs 0.19 0.19
-
3%
6.50 6.50
-
97%
- Selling and Administrative Expenses 7.43 7.43
5% 5%
111%
- Research and Development Expense 13 13
10% 10%
199%
-14 -14
32% 32%
-212%
- Depreciation and Amortization 0.19 0.19
5% 5%
3%
EBIT (Operating Income) EBIT -14 -14
32% 32%
-215%
Net Profit -18 -18
17% 17%
-270%

In millions CHF.

Don't miss a Thing! We will send you all news about Newron Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Newron Pharmaceutical Stock News

EQS
16 days ago
Im Rahmen der Lizenzvereinbarung erhält Newron für die vollständigen Rechte in den lizenzierten Regionen von EA Pharma insgesamt bis zu EUR 117 Mio., einschließlich einer Abschlagszahlung in Höhe von EUR 44 Mio., finanzieller Beiträge zu der bevorstehenden einjährigen Phase-III-Studie, die außerh...
EQS
16 days ago
Dieses Dokument enthält zukunftsbezogene Aussagen, die (auf nicht erschöpfende Weise) folgende Themen betreffen: (1) die Fähigkeit von Newron, die Geschäftsfelder weiterzuentwickeln und auszubauen, die Entwicklung der aktuellen Produktkandidaten erfolgreich abzuschließen; den Zeitpunkt des Beginn...
More Newron Pharmaceutical News

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Head office Italy
CEO Stefan Weber
Founded 2002
Website www.newron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today